The objective of NABATIVI is to identify and validate novel drug targets
in order to select lead compounds
for future development of a new class of anti-infective drugs against Gram-negative bacteria
. This objective impacts on the increasing emergence and spread of antimicrobial drug resistant pathogens in Europe and the rest of the world and conforms to the aim of the FP7-HEALTH to contribute to international efforts addressing global health problems, such as antimicrobial drug resistance.
One priority of the area of antimicrobial drug resistance within FP7-HEALTH is the discovery of new and urgently needed antibiotics.
The proposed work is organised into ten research work packages (WPs), one dissemination and exploitation WP and the project management WP. The research work includes three major steps to identify novel drugs against multi-resistant P. aeruginosa and B. cenocepacia: